(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc. · Breast Neoplasms · Invasive Breast Cancer
Phase 2
Active, not recruiting
87
2026-07
Industry sponsor intelligence
Atossa Therapeutics, Inc.Clinical Pipeline.
Lead-sponsor view of Atossa Therapeutics, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 87
Pipeline overview
Programs by phase and activity.
Velocity
Atossa Therapeutics, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Goserelin → | 1 | 0 | 1 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Atossa Therapeutics, Inc. studies.
This page groups studies where Atossa Therapeutics, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates